Category Archives: HCP

About Rethymic HCP

HCP – Clinical Trials

The safety and efficacy of RETHYMIC® (allogeneic processed thymus tissue–agdc) was evaluated in 105 patients across 10 clinical trials. The effectiveness of RETHYMIC was evaluated in 95 of those patients with congenital athymia in 10 clinical trials with follow-up of … Continue reading →

HCP – Educational Resources

As you discuss the care of your patient with their family or caregiver, you may find these materials and organizations helpful. Medical Literature These articles are provided by Enzyvant for your education and for discussion of FDA-approved use. RETHYMIC® (allogenic … Continue reading →

HCP – How to access Treatment

RETHYMIC® (allogeneic processed thymus tissue–agdc) is currently available at one location in Durham, North Carolina. To obtain the contact information for the single site of administration in Durham, North Carolina, please contact Enzyvant Medical Information at +1 833 369 9868 … Continue reading →

HCP – After Treatment

How long does it take for RETHYMIC to work? Immune reconstitution sufficient to protect from infection is unlikely to develop prior to 6-12 months after treatment with RETHYMIC5. For some patients elevated naïve T cell numbers are not observed until … Continue reading →

HCP – About Us

Learn about the diagnostic pathway for congenital athymia, including how to differentiate it from Severe Combined Immunodeficiency (SCID), and about the different phenotypes of congenital athymia. What is congenital athymia? Congenital athymia is an ultra-rare primary immunodeficiency which is characterized … Continue reading →

HCP – Patient Support

Supporting the treatment journey Enzyvant CONNECT is here to provide personalized support throughout your child’s treatment journey with RETHYMIC® (allogeneic processed thymus tissue–agdc). The Enzyvant CONNECT team will assist families with:

Main HCP

A guide about congenital athymia for healthcare providers Congenital athymia is an ultra-rare condition characterized by the absence of a thymus at birth.1 Estimated incidence in the United States is approximately 17 to 24 infants for every 4 million live … Continue reading →

Indication and Important Safety Information

IMPORTANT SAFETY INFORMATION

Infection Control: Immune reconstitution sufficient to protect from infection is unlikely to develop prior to 6-12 months after treatment with RETHYMIC. Immune reconstitution is needed for the body to produce cells in the immune system to fight infection. Your child’s doctor should advise you of infection control measures which should be followed immediately after treatment and until the immune system starts working at a sufficient level. Monitor your child closely for signs of infection, including fever. Your child should be maintained on immunoglobulin replacement and prophylactic antimicrobials until certain criteria are met as determined by your doctor.

Graft versus Host Disease (GVHD): RETHYMIC may cause or make pre-existing GVHD worse. Your child will be monitored for GVHD and treated if needed. Symptoms of GVHD may include fever, rash, enlarged lymph nodes, inflammation of the gastrointestinal system and/or diarrhea.

Autoimmune Disorders: Autoimmune-related adverse events occurred in patients treated with RETHYMIC. These events included: low platelets, low white blood cells, protein in urine, low red blood cells, hair loss, poor thyroid function, inflammation of liver, inflammation of the joints, inflammation of the spinal cord, loss of pigment in the skin, eyes and hair, overactive thyroid function, and loss of function of the ovaries. Your doctor will monitor your child regularly including performing blood tests.

Kidney Disease: Treatment with RETHYMIC is a risk factor for death in patients with pre-existing kidney disease.

Cytomegalovirus (CMV) Infection: In clinical studies with RETHYMIC, 4 out of 4 patients with pre-existing CMV infection prior to the implantation with RETHYMIC died. Talk to your doctor about the benefits/risks of treatment if your child has pre-existing CMV infection.

Cancer: Due to your child’s weakened immune system, there is increased risk of developing certain cancers. Your child’s doctor will monitor your child through testing for Epstein-Barr virus (EBV) and cytomegalovirus (CMV), which are two viruses that can cause cancer.

Transmission of Serious Infections: Because RETHYMIC is made from human tissue, and animal products are used in the manufacturing process, transmission of infectious diseases may occur.

Vaccinations: Your child should not receive any vaccinations until he or she has met certain requirements set by your doctor. Talk to your child’s doctor prior to any vaccinations.

Anti-HLA Antibodies: Prior to receiving RETHYMIC your child will be tested for HLA antibodies, which are proteins that may be present in your child’s blood. If your child has these antibodies, he/she will need to receive RETHYMIC from a donor that does not express those HLA proteins.

HLA Typing: If your child has received a hematopoietic cell transplantation (HCT) or a solid organ transplant, they will have a test to look for specific antibodies that could interfere with the effect of RETHYMIC. If they are present, then it will be necessary to receive RETHYMIC from a certain group of donors that do not have these proteins.

Deaths: 105 children participated in the clinical studies of RETHYMIC. 29 of the patients died, including 23 in the first year after implantation of RETHYMIC.

What are the most common side effects with RETHYMIC?

The most common side effects with RETHYMIC are hypertension (high blood pressure), cytokine release syndrome, rash, hypomagnesemia (low magnesium), renal impairment / failure (decrease of kidney function), thrombocytopenia (low platelets), and graft versus host disease.

These are not all of the possible side effects of RETHYMIC. Talk to your child’s doctor about any side effect that bothers your child or does not go away.

You are encouraged to report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/safety/medwatch.

INDICATION

RETHYMIC® (allogeneic processed thymus tissue–agdc) is indicated for immune reconstitution in pediatric patients with congenital athymia.

RETHYMIC is not for use in patients who have been diagnosed with severe combined immunodeficiency (SCID).

Indication and Important Safety Information

IMPORTANT SAFETY INFORMATION

Kidney Disease: Treatment with RETHYMIC is a risk factor for death in patients with pre-existing kidney disease.

Transmission of Serious Infections: Because RETHYMIC is made from human tissue, and animal products are used in the manufacturing process, transmission of infectious diseases may occur.

Vaccinations: Your child should not receive any vaccinations until he or she has met certain requirements set by your doctor. Talk to your child’s doctor prior to any vaccinations.

Deaths: 105 children participated in the clinical studies of RETHYMIC. 29 of the patients died, including 23 in the first year after implantation of RETHYMIC.

What are the most common side effects with RETHYMIC?

These are not all of the possible side effects of RETHYMIC. Talk to your child’s doctor about any side effect that bothers your child or does not go away.

You are encouraged to report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/safety/medwatch.

INDICATION

RETHYMIC® (allogeneic processed thymus tissue–agdc) is indicated for immune reconstitution in pediatric patients with congenital athymia.

RETHYMIC is not for use in patients who have been diagnosed with severe combined immunodeficiency (SCID).

Category Archives: HCP

About Rethymic HCP

HCP – Clinical Trials

HCP – Educational Resources

HCP – How to access Treatment

HCP – After Treatment

HCP – About Us

HCP – Patient Support

Main HCP

Pages

Archives

Categories

Indication and Important Safety Information

IMPORTANT SAFETY INFORMATION

INDICATION

Indication and Important Safety Information

IMPORTANT SAFETY INFORMATION

INDICATION